Opus Genetics Solidifies Leadership Position in Gene Therapy Development for Inherited Retinal Diseases with Strategic Long-Term Financing by Oberland Capital
– Agreement includes up to $155 million in non-dilutive funding with an upfront payment of $35 million and a $5 million equity investment – Strategic
